洞察市场格局
解锁药品研发情报

400客服电话

  • 购买数据产品

    400-9696-311 转1

  • 定制咨询业务

    400-9696-311 转2

  • 数据与AI定制业务

    400-9696-311 转3

  • 商务合作及其他问题

    400-9696-311 转4

  • 投诉及建议

    400-9696-311 转5

医药数据查询

【ChiCTR2400093928】Impact of calligraphy practice on functional brain network

基本信息
登记号

ChiCTR2400093928

试验状态

尚未开始

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2024-12-13

临床申请受理号

/

靶点

/

适应症

/

试验通俗题目

Impact of calligraphy practice on functional brain network

试验专业题目

Effect of calligraphy practice on modulating default mode network in older adults at risk of dementia – a randomized controlled trial

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

联系人通讯地址
请登录查看
临床试验信息
试验目的

The primary objective is to examine the effect of calligraphy practice on functional connectivities (FCs) within DMN. The secondary objective is to examine the effect of calligraphy practice on cognitive functions.

试验分类
请登录查看
试验类型

随机平行对照

试验分期

其它

随机化

Participants will be randomly allocated to either the intervention or control group in a 1:1 ratio using a central computer-generated random number sequence.

盲法

Research staff who assist in intervention will not assess outcomes, and those who assess outcomes will be blinded to allocation and not involved in intervention delivery.

试验项目经费来源

/

试验范围

/

目标入组人数

100

实际入组人数

/

第一例入组时间

2025-01-01

试验终止时间

2027-12-31

是否属于一致性

/

入选标准

Inclusion criteria are ethnic Chinese, aged 55 to 75 years, right-handed, living at home, and experiencing SCD as defined by i) scoring above the age- and education-specific cutoff for MCI (i.e., cognitive test performance within normal range) in the Hong Kong Chinese version of Montreal Cognitive Assessment (MoCA), and ii) answering yes to at least one question in the Abbreviated Memory Inventory for Chinese, a locally validated screening tool for SCD.;

排除标准

Exclusion criteria include living in care homes; known MCI or clinical dementia; having history of stroke, traumatic brain injury, Parkinson’s disease, epilepsy, brain tumor, or prior operation to the brain; taking drugs that affect cognition (benzodiazepines, cognitive enhancers, etc.); having history of depression, bipolar affective disorder, psychosis, or substance abuse; having significant impairment in communication, writing or mobility; previously learned or already practising Chinese calligraphy handwriting; already attending other cognitive interventions or participating regularly in other cognitive activities (≥1 hour per week; cognitive activities defined by the validated classification system of leisure activities in local older Chinese adults); and having magnetic resonance imaging (MRI) contraindications.;

研究者信息
研究负责人姓名
请登录查看
试验机构

Chinese University of Hong Kong

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

/

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

Chinese University of Hong Kong的其他临床试验

Chinese University of Hong Kong的其他临床试验

最新临床资讯

摩熵医药企业版
50亿+条医药数据随时查
7天免费试用

全球药物研发中心
全球研发数据与行业前沿情报

385,639
全球在研药物数
0
本月临床试验数
全球批准的新药
更多
全球首批
各国首批
数据来源:摩熵医药
更新时间:
研发动态
相关报告
政策法规
更多信息,请进入全球药物研发中心查看

医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测

2,632亿元
2026年Q2总销售额
6.14%(2026Q2)
TOP5企业市场份额
药品销售排行榜
查看完整数据
2025Q4医院化学药销售增速 *按市场份额排序
  • 1
    甲氨蝶呤注射液
  • 2
    克霉唑阴道乳膏
  • 3
    氯化钠注射液
核心能力
  • 医药市场销售数据分析 · 医院、实体药店、网上药店
  • 市场竞争格局分析(靶点、药品类型、ATC大类)
更多信息,请进入医药市场洞察中心查看